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Importance of nitric oxide in the control of renal hemodynamics. The
kidney vasculature is under tonic control by nitric oxide (NO) and in
cortex, NO controls RA and Kf. Systemic NO inhibition leads to systemic
hypertension, increases in RE, mediated by Ang II and ET, and direct
effects on RA and Kf. The relationship between NO and other vasocon-
strictor systems is variable. In the conscious relaxed animal, vasoconstric-
tor activity is low, yet acute NO inhibition leads to pressor and renal
vasoconstrictor reponses. At physiologic levels, FT unexpectedly is a renal
vasodilator, possibly via NO generation at RA. When vasoconstrictor
activity is high, NO is very important in maintenance of renal perfusion.
Chronic L-NAME produces dose dependent systemic and glomerular
capillary hypertension and eventual proteinuria and glomerular damage.
NO deficiency is key in this process, although the hypertension becomes
refractory to L-arginine administration and dependent on Ang II and the
SNS, by mechanisms not yet defined. In contrast, the renal vasculature
remains fully responsive to L-arginine, suggesting that pressor and renal
vascular responses to chronic NO inhibition are separately regulated. NO
generated from iNOS does not normally control BP or renal hemodynam-
ics. The relative contributions of NO from bNOS and eNOS, and
importance of NOS in different locations in the kidney, remain to he
determined.
Nitric oxide (NO) is a simple messenger molecule, made from
L-argininc by the enzymatic action of several nitric oxide syn-
thases (NOS). The different isoforms of NOS are widely distrib-
uted. The brain type NOS, bNOS and the vascular endothelial,
eNOS are constitutively expressed enzymes. The macrophage
inducible NOS, iNOS, is induced in high quantities by immuno-
logical stimulation [1], although there may be a basal "constitu-
tive" expression of iNOS in some locations [2]. Vascular tone is
partly controlled by NO generated from eNOS, activated by shear
stress [1]. The bNOS is more abundant and widely distributed
than eNOS and both central and peripheral neural activity
influences systemic and/or regional vascular tone [1, 3]. Under
some pathological conditions, NO generated from vascular iNOS,
can cause profound hypotension [1].
The production of NO is determined by the type and quantity
of NOS present and by availability of co-factors and substrate [1].
Several L-arginine analogs inhibit NO synthase [11. Drugs such as
N monomethyl L-arginine (L-NMA), and nitro L-arginine meth-
ylester (L-NAME), are nonselective NOS inhibitors, whereas
glucocorticoids and aminoguanidine preferentially inhibit iNOS
[1, 41. Much of our insight into the physiologic role of NO in
control of renal function has been obtained using inhibitors of NO
Present address: Gladstone Tnstitnte of Cardiovascular Disease,
UCSF, San Francisco, CA 94141, USA.
© 1996 by the International Society of Nephrology
synthesis, and most of the data discussed below deal with studies
employing this approach.
Distribution of NOS in the kidney
In the kidney, as elsewhere, the most abundant NOS identified
is the bNOS, found in glomeruli and vasculature as well as the
macula densa, collecting duct and inner medullary thin limb [5].
Detection of eNOS has been more difficult, although recently
eNOS was found in the arcuate and interlobular arteries, afferent
arterioles and the glomerulus using RT-PCR [6]. Presumably
eNOS is also present throughout the vascular endothelium of the
renal circulation, although functional evidence, discussed below,
suggests that the efferent arteriolar resistance (RE) is not under
tonic NO dependent control [7]. In addition, two structurally
distinct iNOS occur constitutively in the rat kidney with a wide
distribution, which includes vascular smooth muscle at the juxta-
glomerular apparatus and tubule epithelium in various segments
[1, 2]. In response to immunological stimuli, iNOS have been
reported throughout the tubule, as well as in mesangial cells,
vascular endothelial cells, and vascular smooth muscle cells [1].
NO and renal hemodynamics
Acute studies
Systemic NO inhibition. In several species systemic administra-
lion of the non-specific NO inhibitors produces dose dependent
increases in BP and RVR with falls in RPF and smaller declines
in GFR [1, 8, 9]. As shown in Figure 1, NOS inhibition in the
conscious chronically catheterized rat, produces -—-35% increase in
BP and —100% increase in RVR, leading to a fall in RPF and a
smaller fall in GFR due to an increase in filtration fraction [9].
These effects persist for the duration of NO synthesis inhibition,
which is particularly impressive since all buffer mechanisms
(which should serve to blunt the effect of loss of one vasoactive
control system) are operative in the conscious animal. There are
regional differences in the extent to which NO controls the
circulation, and the renal vaseulature appears to be particularly
sensitive since systemic infusion of low doses of NOS inhibitors,
which have no effect on BP, and intrarcnal administration of NOS
inhibitors, produce increased RVR with reductions in RPF [1, 7,
8, 10].
In vivo glomerular micropuncture studies have shown that
systemic NO inhibition causes marked increases in both preglo-
merular (RA) and efferent arteriolar (Re) resistances, Figure 2 [7,
11]. As a result, glomerular plasma flow falls but SNGFR is
relatively protected due to the large rise in glomerular blood
pressure (PGC) resulting from the increased BP and RE. In
addition, the glomerular capillary ultrafiltration coefficient (Kf) is
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Fig. 1. The effect af acute NO blockade (10mg/kg, L-NAME i.v.) on mean
arterial blood pressure (BP), renal vascular resistance (R VR), GFR, renal
plasma flow (RPF), and filtration fraction (FF) in the conscious chronically
catheterized rat. Data shown as mean 1 SE, *significant difference from
the control value. Data are obtained from 191.
reduced [7, 11], probably mediated by mesangial cell contraction,
since in vitro NO relaxes the glomerular mesangial cell [1].
Local, intrarenal NO inhibition. Since systemic NO inhibition
produces widespread inhibition of NOS and increases in BP, it is
difficult to discriminate between direct intrarenal versus indirect
effects of NOS inhibition. Local intrarenal inhibition of NO
generation causes smaller increases in RVR than are seen during
systemic NO inhibition [7, 8]. As shown in Figure 2, intrarenal NO
inhibition increases RA, but has no effect on RE while exhibiting
the similar Kf reducing effect seen with systemic NOS inhibition
[7]. In vitro studies on isolated microperfused cortical arterioles
have supported our in vivo observation that intrarenal generation
of NO control RA but not RE in cortical vessels, although in
contrast, NOS inhibition constricts both RA and RE of the in vitro
juxtamedullary nephron preparation [1. In some situations, the
cortical efferent arteriole can make and respond to NO, and NOS
has been localized in R as well as RA [1, 5]. The increased RE,
seen with systemic NO inhibition when blood pressure rises, is
therefore not apparently due to inhibition of locally generated
NO, but reflects some secondary phenomena (see below).
NOS is abundant at the juxtaglomerular apparatus and NO
generated within the macula densa controls glomerular hemody-
namics via the tubuloglomerular feedback (TGF) system, provid-














the increase in RA to an increase in systemic BP [121. NO may also
influence the myogenic component of autoregulation, but al-
though there is a suggestion that NO contributes to low pressure
dilation of RA, renal autoregulatory ability is relatively intact
during NO inhibition, although RVR is reset to a higher value [1].
Furthermore, acute NO inhibition reduces inner medullary blood
flow and interferes with the pressure natriuresis [13].
Interactions with other vasoconstrictor systems. As discussed
above, acute NO inhibition leads to significant renal vasoconstric-
tion. This vasoconstriction could result either from withdrawal of
an active NO vasodilatory stimulus and/or from amplification of
underlying vasoconstrictor systems. Below we consider the inter-
actions between NO and other vasoconstrictor control systems.
(a) Angiotensin II. The response to systemic NO inhibition
closely resembles the response to angiotensin II (Ang II) infusion
[1]. However, blockade of the endogenous Ang II system has no
effect on either the pressor or the renal vasoconstrictor response
to systemic NO inhibition in the conscious chronically catheter-
ized rat [141, a preparation in which endogenous levels of Ang II
are low, and are not tonically controlling renal hemodynamics.
When the Ang II system is acutely activated (volume depletion,
surgical stress), or when exogenous Ang II levels are raised by
infusion, the renal vasoconstrictor response to acute NOS inhibi-
tion is greatly amplified by the high level of Ang II [1, 151. The
mechanism(s) by which NO and Ang TI interact when Ang II
levels are high, is unclear and may involve interactions at the
receptor level as well as NO dependent control of Ang II levels via
control of renin release [1].
In the anesthetized animal acutely prepared for micropuncture,
some activation of the renin-angiotensin system is inevitable, and
we have preliminary micropuncture data that suggest that this
activated Ang II does contribute to the glomerular microcircula-
tory changes seen with systemic NO inhibition [16]. Concomitant
Ang TI blockade with losartan attenuates the increases in BP, RA,
and particularly RE, and the reduction in Kf seen with systemic
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Fig. 2. Effect of systemic NO blockade (NMA, 30mg/kg bolus, 2 mg/kg/mm,
iv.) and intrarenal NO blockade (NMA, 3 mg/kg bolus, 0.2 mg/kg/mm,
intrarenal arte,y) on preglomendar resistance (R,j, efferent arteriolar resis-
tance (R,), and the ultrafiltration coefficient (K). The data are shown as
percent change (%) from control, and are taken from [7].
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Blantz and Gabbai also suggested that endogenous Ang II medi-
ates some of the glomerular hemodynamic responses to acute
systemic NO inhibition in the anesthetized animal [17].
(b) Endothelin. Endothelin (ET) receptors are widely distrib-
uted throughout the vasculature, and while there are both ETA
and ET receptors in the kidney, recent evidence suggests that ET
induced renal vasoconstriction in the normal kidney is via ETa
stimulation [18]. Acute systemic NO inhibition both potentiates
the vasoconstrictor actions of ET and also enhances the synthesis
and release of ET [19]. In the conscious chronically catheterized
rat we found that the increases in BP and RVR seen with acute
systemic NO synthesis inhibition were attenuated by concomitant
inhibition of ET using either the ET converting enzyme inhibitor
phosphoramidon or the mixed ET receptor antagonist, bosentan
(which blocks both ETA, and ETB receptor subtypes; Fig. 3). The
falls in RPF and GFR due to acute NO inhibition were not
blunted by ET inhibition, suggesting that in the conscious rat, ET
inhibition modifies renal hemodynamics secondary to the blunted
pressor effect [20]. We also have preliminary data in the anesthe-
tized micropunctured rat, where the pressor, renal vasoconstric-
tor, and K5 lowering effects of acute systemic NO inhibition
(+NMA) are attenuated by ET blockade. Of particular note, the
increase in RE is particularly attenuated by ET inhibition [16].
These studies together with the observations with acute Ang II
receptor inhibition (see above) suggest that the increase in RE
with systemic but not local intrarenal NO inhibition, is the result
of secondary effects of ET and Ang II [16].
In the course of these studies we conducted control experiments
investigating the effect of ETA and ET receptor blockade on the
renal vasculature in the normal baseline state. As shown in Figure
3, unexpectedly, blockade of ETA and ET receptors produced a
paradoxical constriction of the preglomerular resistance vessels,
suggesting that the physiologic action of ET on the glomerular
microcirculation is as a vasodilatory agent [21]. Since selective
ETA blockade (with BQI 23) has no effect on RA, [21] this atypical
vasodilatory response to ET is mediated via the ETu receptor and
presumably reflects ETu mediated release of NO and/or POT2.
(c) Sympathetic nervous system (SNS). The role of the SNS in
the vasoconstrictor responses to acute NO inhibition is controver-
sial. Some workers report that SNS inhibition (ganglion blockade,
pithing, or adrenergic receptor inhibition) has little effect on the
increase in BP and RVR seen with acute NO inhibition. In
contrast, others report that the hypertension and renal vasocon-
strictinn is at least partly due to both central and peripheral
sympathetic activation [1]. Recent evidence suggests that the renal
vasoconstriction seen during acute systemic NO inhibition is
partially the result of increased renal nerve activity [22]. We have
recently investigated the effect of chronic bilateral renal denerva-
tion on the renal responses to acute systemic NO inhibition and to
stimulation of renal NO synthesis with L-arginine infusion [23]. In
the conscious unstressed preparation where efferent renal sympa-
thetic nerve activity is low, we found that renal denervation had no
impact on the renal hemodynamic responses to either NO inhi-
bition or NO stimulation.
Overall, withdrawal of NO amplifies any vasoconstrictor sys-
tems that are currently active. However, in the basal relaxed state,
when vasoconstrictor systems are dormant we still see marked
renal vasoconstricor responses to acute NO inhibition, suggesting
that tonically, NO exerts a direct vasodilatory effect on the renal
microcirculation.
Chronic studies
Hemodynamic and structural effects of chronic NO inhibition. It is
possible to produce a sustained hypertension by chronic adminis-
tration of NO inhibitors such as L-NAME. In studies by us, partial
NO inhibition for eight weeks in the rat produced moderate,
stable hypertension, marked renal vasoconstriction, with constric-
tion of both preglomerular and efferent resistance vessels, as well
as reductions in K. Because of the sustained systemic hyperten-
sion and increase in R0,glomerular blood pressure is chronically
elevated and these rats display moderate proteinuria and histo-
logic evidence of structural damage with a mild increase in focal
and segmental glomerular sclerosis [241. In this model only slight
falls in GFR are seen. Ribeiro and colleagues used a higher dose
of L-NAME in the drinking water, to produce near complete NO
inhibition in rats for four to six weeks [25]. This produced severe
and sometimes malignant hypertension with widespread structural
damage and large falls in GFR. More complete NO inhibition
leads to further elevations in P0, which probably contributes to
the increased glomerular injury in the more severe models [1, 241,
although withdrawal of the growth inhibitory actions of NO [26]
may also contribute to the development of glomerular injury.
Mechanisms of the hypertension. (a) Role of NO deficiency. The
basis for this hypertension, produced by chronic administration of
L-arginine analogs, is clearly NO deficiency and as expected,
24-hour urinary nitrite plus nitrate excretion (UNOxV; indicative
of NO production) is markedly depressed in chronically NO
blocked animals [27]. The 24-hour UNOXV do not correlate
quantitatively and inversely with the level of hypertension, how-
ever, since we have found that administration of very high dose
L-NAME produces further increments in BP without further
depressing 24-hour UNOXV [28 and unpublished data].
The response to L-arginine administration alters as the chronic
NO inhibition induced hypertension evolves, suggesting that the
factors responsible for the maintenance of the hypertension
change. L-arginine is the native substrate for NO and competi-
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Fig. 3. The effect of acute systemic endothelin (ET) blockade using the
nonselective receptor antagonist, bosentan (10 mg/kg, i. v.), on preglomernlar
resistance (RA, •) and efferent arteriolar resistance (RD 0) in the normal
euvolemic rat. These data are taken from [21].
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Fig. 4. The effect on blood pressure (BP) and renal vascular resistance
(RVR), in the conscious chronically catheterized rat, in response to acute NO
blockade (left panel, 10 mg/kg, iv. L-NAME) and chronic NO blockade
(right panel, daily oral NAME, 10mg/kg per 24 hr for 4 to 5 weeks). The effect
of acute L-arginine infusion (L-Arg, bolus 300 mg/kg, 50 mg/kg per mm)
on acute and chronic NO blockade, is shown by the hatched columns. Data
are taken from [9, 30].
administration of L-arginine, together with the L-arginine analog,
L-NAME, prevents any increase in BP [291, but after one week of
chronic L-NAME administration in rats acute L-arginine infusion
is only capable of partially reversing the increased BP [25]. As
shown in Figure 4, we have recently reported that after four to five
weeks of chronic L-NAME, acute L-arginine has little effect on
BP [30], although remarkably, the kidney vasodilates normally to
the NO substrate, with RVR returning to control values.
Thus, although there is clearly a major role for NO deficiency in
L-NAME induced hypertension, the diminishing ability to reverse
the hypertension with L-arginine suggests that simple competitive
inhibition of NO production is not the only mechanism. Structural
vascular changes (hypertrophy of resistance vessels) may also be
involved although other functional hypertensive mechanisms are
also apparently activated [31].
(b) Role of other vasoconstrictor systems. A number of studies
have provided clear evidence that Ang II plays a primary role in
the pathogenesis of chronic NO inhibition-induced hypertension.
Chronic Ang II inhibition with either receptor antagonists, or
converting enzyme inhibitors, ameliorates the hypertension and
renal dysfunction and blunts or prevents the arteriolar and
glomerular injury seen with chronic NO inhibition [25, 31, 32].
Despite these findings, acute Ang II blockade alone has little
effect on BP or RVR in anesthetized or awake rats with chronic
NO inhibition-induced hypertension [33, 31. However, when
acute Ang II blockade is combined with al adrenergic blockade in
the conscious rat, the BP is almost normalized, whereas RVR
remains elevated [31. There is other evidence that alterations in
both the central and peripheral sympathetic nervous system are
involved in initiation and maintenance of the chronic L-NAME
induced hypertension [1, 22, 35], although the way in which Aug
II and the SNS interact is not yet clear. Based on our findings with
L-arginine and combined Ang II and csl adrenoceptor blockade,
however, it does seem that that the pressor and the renal
hemodynamic responses to chronic L-NAME are separately reg-
ulated [31.
Role of the various NOS isoforms. It is generally anticipated that
NO generated from the constitutive endothelial and possible
neuronal NOS plays a major role in control of BP and renal
hemodynamics. Unfortunately, the L-arginine analogs most
widely used to study the effect of chronic NO inhibition are
relatively nonspecific and block all NOS isoforms when adminis-
tered in high doses. We have conducted preliminary studies in
which chronic iNOS inhibition has been produced in the normal,
conscious chronically catheterized rat, using daily oral aminogua-
nidine [36]. There are no effects on BP or renal hemodynamics
with two weeks of continual iNOS inhibition, suggesting that at
least in rats on a normal dietary salt intake, iNOS, wherever
located, have little role or control of blood pressure. Studies are
currently underway in a number of laboratories, using the selec-
tive bNOS inhibitors in order to describe the roles of this isoform
in the control of renal hemodynamics.
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